Latent Membrane Protein 1 Promotes Tumorigenesis Through Upregulation of PGC1β Signaling Pathway
Open Access
- 9 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Stem Cell Reviews and Reports
- Vol. 17 (4), 1486-1499
- https://doi.org/10.1007/s12015-020-10112-8
Abstract
Natural killer/T-cell lymphoma (NKTCL) is an aggressive Epstein-Barr virus (EBV)-associated non-Hodgkin lymphoma with poor prognosis. In this study, we aimed to investigate the potential mechanism of latent membrane protein 1 (LMP1)-mediated tumorigenesis and provide a novel therapeutic strategy for targeting the EBV DNA genome. We found that LMP1 upregulated the expression of peroxisome proliferator-activated receptor-γ (PPARγ) coactivator-1β (PGC1β) through activation of nuclear factor-κB (NF-κB). Furthermore, the activated PGC1β upregulated the expression of 8-oxoguanine DNA glycosylase (OGG1) through the coactivation of nuclear respiratory factor 1 (NRF1) and GA-binding protein α (GABPα), preventing reactive oxygen species (ROS)-mediated base incision in the EBV genome and favoring its survival. Interruption of hexokinase domain component 1 (HKDC1) by either shRNA or Tf-D-HKC8 peptide suppressed the interaction of HKDC1 with voltage-dependent anion channel 1 (VDAC1), triggering mitochondrial dysfunction and excessive generation of ROS, thus resulting in EBV suppression through ROS-mediated DNA damage. Suppression of the EBV genome inhibited the expression of the LMP1/PGC1β/HKDC1/OGG1 signaling pathway, forming a positive feed forward loop for the generation of ROS, hence inhibiting the EBV genome and subsequent EBV-associated tumor development. We concluded that LMP1 triggers EBV-associated tumorigenesis through activation of the PGC1β pathway. This study provided a novel therapeutic strategy for the treatment of EBV-associated tumors by targeting HKDC1. Graphical AbstractKeywords
Funding Information
- National Outstanding Youth Foundation of China (31601172)
- Innovative Research Group Project of the National Natural Science Foundation of China (81772097)
- Sanming Project of Medicine in Shenzhen (SZSM201612004)
This publication has 46 references indexed in Scilit:
- Hexokinase 2 Is Required for Tumor Initiation and Maintenance and Its Systemic Deletion Is Therapeutic in Mouse Models of CancerCancer Cell, 2013
- The Metabolic Regulator ERRα, a Downstream Target of HER2/IGF-1R, as a Therapeutic Target in Breast CancerCancer Cell, 2011
- Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus–mediated B-cell proliferationBlood, 2011
- Transcriptional Control of the ERBB2 Amplicon by ERRα and PGC-1β Promotes Mammary Gland TumorigenesisCancer Research, 2010
- Disruption of the hexokinase–VDAC complex for tumor therapyOncogene, 2008
- Base-excision repair of oxidative DNA damageNature, 2007
- Involvement of mammalian OGG1(MMH) in excision of the 8-hydroxyguanine residue in DNA1,2Free Radical Biology & Medicine, 2002
- Biochemistry and molecular cell biology of diabetic complicationsNature, 2001
- Epstein-Barr virus transformation: involvement of latent membrane protein 1-mediated activation of NF-κBOncogene, 1999
- Genetic polymorphisms and alternative splicing of the hOGG1 gene, that is involved in the repair of 8-hydroxyguanine in damaged DNAOncogene, 1998